酒精相关肝硬化早期移植:整合成瘾治疗与低复饮率
该前瞻性试点项目评估酒精相关肝病患者在戒酒不足6个月时接受肝移植的可行性,通过多学科评估和移植前后成瘾治疗,101例(14%)入选等待名单、44例(6.2%)接受移植,移植后平均随访339天仅3例复饮,生存率与戒酒超6个月对照组无显著差异(P = .07)。
要点
- 酒精相关肝病戒酒不足6个月者经严格筛选可安全接受肝移植。
- 移植前后整合成瘾治疗与随机生物标志物检测可降低复饮率。
- 年轻和较低MELD评分与移植后复饮风险增加相关,戒酒时长非预测因素。
核心结论
- 对戒酒不足6个月的酒精相关肝病患者,通过多学科评估和移植前后成瘾治疗,可安全进行肝移植并降低移植后复饮。
研究设计与样本
- 前瞻性试点项目,2018年5月1日至2020年10月31日共接收703例转诊,经多学科团队评估纳入,最终101例(14%)列入等待名单、44例(6.2%)接受移植。
主要发现
- 移植后平均随访339天,仅3例患者复饮。
- 试点移植组与戒酒超过6个月的对照组生存率无显著差异(P = .07)。
- 多因素分析显示,列入等待名单时较年轻和较低MELD评分与复饮可能性增加相关(P < .05),戒酒时长不是预测因素。
关键数值与推荐
- 纳入标准由多学科团队评估,包括对酒精使用、社会支持和精神共病的深入检查。
- 所有符合纳入标准的患者直接接受预防复饮治疗,移植前后进行随机生物标志物酒精检测。
临床怎么用
- 对于酒精相关肝病需移植但戒酒不足6个月的患者,可考虑在多学科评估和整合成瘾治疗框架下进行早期移植。
- 移植前后应提供预防复饮治疗并采用随机生物标志物检测监测酒精使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In 2018, our team initiated a prospective pilot program to challenge the paradigm of the "6-month rule" of abstinence for patients with alcohol-related liver disease (ALD) requiring transplant. Our pilot involved an in-depth examination of patients' alcohol use, social support, and psychiatric comorbidity, as well as the provision of pre- and post-transplantation addiction treatment. METHODS: Patients with ALD were assessed for inclusion in the pilot by a multidisciplinary team. Relapse prevention therapy was provided directly to all patients deemed to meet the program's inclusion criteria. Random biomarker testing for alcohol was used pre and post transplantation. RESULTS: We received 703 referrals from May 1, 2018 to October 31, 2020. After fulfilling the program's criteria, 101 patients (14%) were listed for transplantation and 44 (6.2%) received transplants. There were no significant differences in survival rates between those receiving transplants through the pilot program compared with a control group with more than 6 months of abstinence (P = .07). Three patients returned to alcohol use during an average post-transplantation follow-up period of 339 days. In a multivariate analysis, younger age and lower Model for End-Stage Liver Disease scores at listing were associated with an increased likelihood of a return to alcohol use (P < .05); length of abstinence was not a predictor. CONCLUSIONS: Our prospective program provided direct monitoring and relapse prevention treatment for patients with ALD and with less than 6 months of abstinence and resulted in a reduction of post-transplantation return to drinking. This pilot study provides a framework for the future of more equitable transplant care.
引用
- Carrique L, Quance J, Tan A, et al. Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment With Low Rate of Relapse. Gastroenterology. 2021. PMID: 34370999. doi:10.1053/j.gastro.2021.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。